Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) today announced the creation of CASiGEN Pharma Ltd. (CASiGEN) to bring new treatments for diabetes and other metabolic disorders to the global market.

ROCHESTER, Minn. -- The Medical Publishing Insights and Practices (MPIP) initiative and its co-sponsors recently collaborated with journal editors to characterize the persistent and perceived credibility gap in reporting industry-sponsored research and to identify potential approaches to resolve it. This unique round table, hosted by MPIP, reached consensus on Ten ...

(Mayo Clinic) The Medical Publishing Insights and Practices initiative and its co-sponsors recently collaborated with journal editors to characterize the persistent and perceived credibility gap in reporting industry-sponsored research and to identify potential approaches to resolve it. This unique round table, hosted by MPIP, reached consensus on "Ten Recommendations for ...

Abbott and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.

Two Michigan State University researchers have invented a protein purifier that could help pharmaceutical companies save time and money.

In this post in the Huffington Post's "Impact" blog, David de Ferranti, president of the Results for Development Institute, and Robert Hecht, managing director at the Institute, examine whether patent pools could help increase access to AIDS drugs among the world's poor, writing, AIDS program managers and advocates must pursue ...

PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee's Pharmaceutical Holdings Limited (Lee's Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention ...

Purdue Pharma L.P. announced today that Intermezzo (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide.

AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.

A newly discovered enzyme brings scientists one step closer to understanding how plants manufacture a molecule with potent medicinal properties.

Alliance Life Sciences Consulting Group, a leading management and technology consultancy, announces the implementation of MemberMATCH at a top-five pharmaceutical manufacturer.

As communities in the United States gather in support of Traumatic Brain Injury (TBI) Awareness Day, BHR Pharma, LLC's SyNAPSe- clinical trial reaches an important enrollment milestone.